Becton Dickinson & Co. closed 20.98% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton, Dickinson and Company BDX, popularly known as BD, is evaluating the divestment of its Life Sciences division as part ...

This was the stock's third consecutive day of losses.

Generation Investment Management, an investment management firm, released its “Global Equity Strategy” fourth quarter 2024 ...

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside ...

Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm ...

Becton, Dickinson and Co. also reported slightly higher pay for the device developer and manufacturer's median worker in ...

Buy rating initiated! Discover why this medtech leader with strong growth prospects & dividends is worth your attention.

In February the company had announced its plan to separate the unit, which consists of biosciences and diagnostic solutions, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Becton, Dickinson & Co (Symbol: BDX) presently has an above average rank, in the top 50% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further ...